Introduction {#s1}
============

Shigellosis, caused by *Shigella* species, is recognized as a major public health burden and continues to be an important cause of diarrheal diseases. Worldwide, *Shigella* episodes were estimated to be 164.7 million annually, of which, 163.2 million were in developing countries, resulting in 1.1 million deaths (Kotloff et al., [@B18]). Epidemics generally occur in underdeveloped and developing countries with poor sanitary conditions where transmission from person to person is common, or when food or water is contaminated by the organism (Qu et al., [@B28]). Despite economic and public health improvements, outbreaks of shigellosis are still reported regularly (Huang et al., [@B15]; Gaynor et al., [@B11]; Kuo et al., [@B19]; Qiu et al., [@B27]). In China, shigellosis has been ranked third in morbidity, and it has become the number one cause of disease-related death in children (Mathers et al., [@B22]).

Based on biochemical and serological properties, the genus *Shigella* is divided into four species or subgroups: *S. flexneri*, *S. dysenteriae*, *S. boydii*, and *S. sonnei*. Among these subgroups, the epidemic subgroup *S. sonnei* caused diarrhea in industrialized countries and *S. flexneri* in developing countries (Kotloff et al., [@B18]). A previous study showed that the annual shigellosis morbidity rate was 20.28 cases per 100,000 people in mainland China from the national surveillance data of 2009, and *S. flexneri* (67.3%) and *S. sonnei* (32.7%) were two major causative species (Sui et al., [@B33]). *S. flexneri* is divided into at least 20 serotypes (serotypes 1a, 1b, 1c, 1d, 2a, 2b, 2 variant, 3a, 3b, 4a, 4av, 4b, 5a, 5b, X, Xv, Y, Yv, F6, and 7b) based on the combinations of antigenic determinants present on the O antigen of the cell envelope lipopolysaccharide (Qiu et al., [@B26]; Sun et al., [@B34]). Serotypes 1c, 4av, 7b, 1d, Yv, 2 variant and Xv are newly reported serotypes in recent years, and some have caused epidemic-level disease (Talukder et al., [@B35]; Stagg et al., [@B32]; Ye et al., [@B37]). Serotype 1c, first appeared in Bangladesh in 1989, was subsequently found to be prevalent in Bangladesh, Egypt, and Vietnam (Carlin et al., [@B6]; El-Gendy et al., [@B7]; Stagg et al., [@B32]). Serotype Xv was first identified in 2000 and later become the predominant serotype in Henan Province between 2002 and 2006. Serotype Xv was also the most prevalent serotype in Gansu and Anhui in 2007 (Ye et al., [@B37]). Therefore, the rapid expansion and spread of novel serotypes pose a severe threat to public health in areas where shigellosis is endemic.

The *S. flexneri* serotype 2 variant (II:3,4,7,8) was first reported by Qiu et al. in 2013 (Qiu et al., [@B26]). During our routine surveillance of bacillary dysentery from 2003 to 2013, a total of 58 serotype 2 variant strains were identified. This novel serotype first appeared in Guangxi in 2003, and then emerged in other provinces. However, no study has yet extensively characterized the newly emerging strains of serotype 2 variant; therefore, an extensive study is needed to determine the emergence, antimicrobial resistance pattern, and epidemic trends of the serotype 2 variant.

Materials and methods {#s2}
=====================

Bacterial isolates, serotyping, and biochemical characterization
----------------------------------------------------------------

Fresh stool samples from diarrhea patients with clinically suspected dysentery were collected in sentinel hospitals. Samples were cultured for *Shigella* by streaking directly onto *Salmonella--Shigella* agar and incubated at 37°C for 18 h. Resultant *Shigella* colonies (colorless, semitransparent, smooth, and moist circular colonies) were routinely grown in a 37°C incubator in Luria--Bertani agar plates (Qu et al., [@B28]). Then, the strains were submitted to our laboratory for further confirmation. This study was approved by the ethics committee of the Academy of Military Medical Sciences (China), and written approval was also obtained from the patients involved in this study. The isolates were confirmed using API 20E test strips (bioMerieux Vitek, Marcy-l\'Etoile, France) following the manufacturer\'s recommendations. Serotypes of *Shigella* isolates were further determined with two serotyping kits: a commercially available kit (Denka Seiken, Tokyo, Japan) and monoclonal antibody reagents (Reagensia AB, Stockholm, Sweden).

Multilocus sequence typing (MLST)
---------------------------------

MLST of these isolates was carried out using the protocols described at <http://www.shigatox.net/ecmlst/cgi-bin/index>. The PCR amplification conditions were as follows: 94°C for 5 min; 33 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min; and 72°C for 10 min with *Ex Taq* DNA polymerase (Takara, Dalian, China). The PCR amplicons of 15 housekeeping genes were sequenced, and sequences were edited using SeqMan 7.0. Then, the sequences were uploaded to the EcMLST website for comparison, which allowed us to determine the sequence type.

Antimicrobial susceptibility testing
------------------------------------

The antimicrobial MICs of 21 antimicrobials including ceftazidime (CAZ), ceftriaxone (CRO), cefepime (FEP), cefoperazone (CFP), cefazolin (CFZ), cefoxitin (FOX), imipenem (IPM), nitrofurantoin (NIT), piperacillin (PIP), ampicillin (AMP), ticarcillin (TIC), tetracycline (TE), tobramycin (TO), gentamicin (GEN), amikacin (AK), aztreonam (ATM), chloramphenicol (C), ticarcillin/clavulanic acid (TIM), levofloxacin (LEV), norfloxacin (NOR), and trimethoprim/sulfamethoxazole (SXT) were determined by broth microdilution using a 96-well microtiter plate (Sensititre, Thermo Fisher Scientific Inc., West Sussex, United Kingdom) according to the manufacturer\'s instructions, and MIC values follow Clinical and Laboratory Standards Institute recommendations. An *Escherichia coli* (ATCC 25922) strain was used as the quality control strain.

Pulsed-field gel electrophoresis (PFGE)
---------------------------------------

All isolates of *S. flexneri* were analyzed by PFGE according to the standard protocol for *S. flexneri* developed by the Centers for Disease Control and Prevention of the USA. *Salmonella enterica* serotype Braenderup H9812 was digested with *Xba*I and used as molecular weight standard. Slices of agarose plugs were digested with *Not*I (Takara, Dalian, China) at 37°C for 3 h. Electrophoresis was carried out in 1% agarose SeaKem Gold gel (Lonza, Rockland, ME, USE) with the CHEF Mapper system (Bio-Rad) with the following run parameters: 6 V/cm and a linear increase in switching times from 2.16 to 54.17 s over a period of 20 h. The interpretation of the PFGE patterns was performed with BioNumerics software version 6.0 (Applied Maths, Sint-Martens-Latem, Belgium). A tree indicating relative genetic similarity was constructed based on the unweighted pair group method of averages and a position tolerance of 1.2%.

PCR amplification of the antibiotic-resistant determinants and integrons
------------------------------------------------------------------------

To understand the underlying mechanism conferring resistance to third-generation cephalosporins, PCR assays (Ahmed et al., [@B1]; Pan et al., [@B23]; Matar et al., [@B21]; Galani et al., [@B10]; Tariq et al., [@B36]) were used to detect the presence of β-lactamase genes such as *bla*~SHV~, *bla*~TEM~, *bla*~OXA~, and *bla*~CTX−M~. The variable regions of class 1 integrons and class 2 integrons were also amplified with primers listed in Table [1](#T1){ref-type="table"}. The primers hep58 and hep59, hep74 and hep51 were used to detect the variable regions of class 1 integrons and class 2 integrons, respectively. The reverse primers *aadA1*, *aadA2*, *aadA5*, and *cmlA1*, together with the forward primer hep58, were used to amplify the gene cassettes of class 1 integron-positive strains. The forward primer hep74 and reverse primer hep51 were used to amplify the gene cassettes of class 2 integron-positive strains. To understand the underlying mechanism conferring resistance to quinolones, plasmid-mediated quinolone resistance determinants (PMQRs) such as *qnrA*, *qnrB*, *qnrD*, *qnrS*, and *aac*(*6′)-Ib-cr* and quinolone resistance--determining regions (QRDRs) of the DNA gyrase (*gyrA*) and topoisomerase IV (*parC*) genes were amplified (Robicsek et al., [@B29]; Hu et al., [@B14]; Pu et al., [@B25]; Tariq et al., [@B36]). Purified PCR fragments were sequenced and analyzed by comparison with sequences in GenBank.

###### 

**Primers for the antibiotic-resistant determinants and integrons**.

  **Target**                         **Primer sequence (5′--3′)**            **Amplicon size (bp)**   **References**
  ---------------------------------- --------------------------------------- ------------------------ -------------------------
  **β-Lactamases**                                                                                    
  *bla*CTX-M-1 group                 F: GGTTAAAAAATCACTGCGTC                 873                      Matar et al., [@B21]
                                     R: TTACAAACCGTCGGTGACGA                                          
  *bla*CTX-M-9 group                 F: AGAGTGCAACGGATGATG                   868                      Matar et al., [@B21]
                                     R: CCAGTTACAGCCCTTCGG                                            
  *bla*CTX-M-2/8/25 group            F: ACCGAGCCSACGCTCAA                    221                      This study
                                     R: CCGCTGCCGGTTTTATC                                             
  *bla*TEM                           F: ATGAGTATTCAACATTTCCG                 1080                     Tariq et al., [@B36]
                                     R: CCAATGCTTAATCAGTGAGG                                          
  *bla*OXA                           F: ATTAAGCCCTTTACCAAACCA                890                      Ahmed et al., [@B1]
                                     R: AAGGGTTGGGCGATTTTGCCA                                         
  *bla*VIM                           F: AGTGGTGAGTATCCGACAG                  509                      Galani et al., [@B10]
                                     R: ATGAAAGTGCGTGGAGAC                                            
  *bla*NDM                           F: GTCTGGCAGCACACTTCCTA                 515                      This study
                                     R: TAGTGCTCAGTGTCGGCATC                                          
  **INTEGRONS**                                                                                       
  IntI1                              F: ACATGTGATGGCGACGCACGA                569                      Pan et al., [@B23]
                                     R: ATTTCTGTCCTGGCTGGCGA                                          
  Class 1 integron variable region   hep58: TCATGGCTTGTTATGACTGT             Variable                 This study
                                     hep59:GTAGGGCTTATTATGCACGC                                       
  Class 1 integron variable region   hep58: TCATGGCTTGTTATGACTGT             Variable                 This study
                                     aadA1:TGTCAGCAAGATAGCCAGAT                                       
  Class 1 integron variable region   hep58: TCATGGCTTGTTATGACTGT             Variable                 This study
                                     aadA2: TGATCTCGCCTTTCACAAA                                       
  Class 1 integron variable region   hep58: TCATGGCTTGTTATGACTGT             Variable                 This study
                                     aadA5: CATCTAACGCATAGTTGAGC                                      
  Class 1 integron variable region   hep58: TCATGGCTTGTTATGACTGT             Variable                 This study
                                     cmlA1: CAACGATTGGGATTTGACGTACTTT                                 
  IntI2                              F: CACGGATATGCGACAAAAAGGT               789                      Pan et al., [@B23]
                                     R: GTAGCAAACGAGTGACGAAATG                                        
  Class 2 integron variable region   hep74: CGGGATCCCGGACGGCATGCACGATTTGTA   Variable                 Ahmed et al., [@B1]
                                     hep51: GATGCCATCGCAAGTACGAG                                      
  **QRDR OF TOPISOMERASE GENES**                                                                      
  *gyrA*                             F: TACACCGGTCAACATTGAGG                 648                      Hu et al., [@B14]
                                     R: TTAATGATTGCCGCCGTCGG                                          
  *gyrB*                             F: TGAAATGACCCGCCGTAAAGG                309                      Hu et al., [@B14]
                                     R: GCTGTGATAACGCAGTTTGTCCGGG                                     
  *parC*                             F: GTACGTGATCATGGACCGTG                 531                      Hu et al., [@B14]
                                     R: TTCGGCTGGTCGATTAATGC                                          
  *parE*                             F: ATGCGTGCGGCTAAAAAAGTG                290                      Hu et al., [@B14]
                                     R: TCGTCGCTGTCAGGATCGATAC                                        
  **PMQR**                                                                                            
  *qnrA*                             F: ATTTCTCACGCCAGGATTTG                 516                      Robicsek et al., [@B29]
                                     R: GATCGGCAAAGGTYAGGTCA                                          
  *qnrB*                             F: GATCGTGAAAGCCAGAAAGG                 469                      Robicsek et al., [@B29]
                                     R: ACGAYGCCTGGTAGTTGTCC                                          
  *qnrD*                             F: CGAGATCAATTTACGGGGAATA               656                      Tariq et al., [@B36]
                                     R: AACAAGCTGAAGCGCCTG                                            
  *qnrS*                             F: ACGACATTCGTCAACTGCAA                 417                      Robicsek et al., [@B29]
                                     R: TAAATTGGCACCCTGTAGGC                                          
  *aac(6′)-Ib-cr*                    F: GCAACGCAAAAACAAAGTTAGG               560                      Pu et al., [@B25]
                                     R: GTGTTTGAACCATGTACA                                            

Results {#s3}
=======

Bacteria isolation and biochemical characterization
---------------------------------------------------

During the routine surveillance of shigellosis in our laboratory, we screened 1813 *S. flexneri* isolates collected from the eastern, western, southern, northern and central regions of China during 2003--2013. In the 11-year surveillance of *Shigella* infections, a total of 58 *S. flexneri* serotype 2 variant isolates were identified. The serotype 2 variant first appeared in Guangxi Province in 2003, then emerged in Shanghai City and Xinjiang Province in 2004, and it was found in Henan Province in 2008. Among the 58 serotype 2 variant isolates, 34 isolates were collected from Shanghai City during the period 2005--2013, 12 isolates were collected from Henan Province during the period 2008--2010, eight isolates were collected from Xinjiang Province during the period 2004--2012, and four isolates were collected from Guangxi Province during the period 2003--2007 (Figure [1](#F1){ref-type="fig"}; see also Table [S1](#SM1){ref-type="supplementary-material"} in the Supplemental Material). Notably, serotype 2 variant has emerged as a common serotype (3.2%), with 2a (32.6%), X variant (25.2%), 1a (9.4%), X (6.3%), 2b (5.4%) and 1b (3.6%) during 2003--2013 (Figure [2](#F2){ref-type="fig"}). In addition, all examined strains of *S. flexneri* serotype 2 variant displayed the same typical biochemical features of *Shigella* species with the ability to ferment glucose, arabinose, mannitol, and melibiose.

![***Shigella flexneri* species distribution from 2003 to 2013 in China**.](fmicb-06-00435-g0001){#F1}

![***S. flexneri* species proportions from 2003 to 2013 in China**.](fmicb-06-00435-g0002){#F2}

Antimicrobial susceptibility testing
------------------------------------

Fifty-eight *S. flexneri* serotype 2 variant isolates were tested for MICs with 21 antimicrobials. Resistance to ampicillin was the most common (57, 98.3%), followed by ticarcillin (56, 96.6%), tetracycline (55, 94.8%), chloramphenicol (54, 93.1%), trimethoprim/sulfamethoxazole (25, 43.1%), norfloxacin (22, 37.9%), cefazolin (22, 37.9%), ceftriaxone (20, 34.5%), cefoperazone (17, 29.3%), piperacillin (14, 24.1%), tobramycin (7, 12.1%), gentamicin (5, 8.6%), ticarcillin/clavulanic acid (3, 5.2%), cefoxitin (3, 5.2%), nitrofurantoin (2, 3.4%), aztreonam (2, 3.4%), and levofloxacin (1, 1.7%). None of the isolates were resistant to cefepime, imipenem, ceftazidime, and amikacin. In addition, strains intermediately resistant to ceftazidime, cefoperazone, levofloxacin, norfloxacin, piperacillin, tobramycin, gentamicin, aztreonam, and ticarcillin/clavulanic acid were also observed (Table [2](#T2){ref-type="table"}). Furthermore, 57 of 58 *S. flexneri* serotype 2 variant isolates exhibited multidrug-resistant (MDR; resistant to three or more classes of antimicrobials), and only one strain from Shanghai was not. All of the isolates had 26 antibiotic-resistance profiles, dominated by resistance to TE/TIC/AMP/C (14/58, 24.1%), followed by TE/TIC/AMP/C/SXT (8/58, 13.8%), TE/TIC/AMP/C/SXT/NOR (5/58, 8.6%), and TE/TIC/AMP/C/NOR (3/58, 5.2%) (Table [3](#T3){ref-type="table"}).

###### 

**Comparison and antimicrobial susceptibility to 21 antibiotics among *S. flexneri* serotype 2 variant isolates from different regions**.

  **Antibiotic**                  **Antimicrobial resistance rate No. (%)**                                        
  ------------------------------- ------------------------------------------- ------------ ----------- ----------- ----------
  Ceftazidime                     0                                           0            0           0           0
  Ceftriaxone                     20 (34.5%)                                  12 (35.3%)   4 (33.3%)   4 (50%)     0
  Piperacillin                    14 (24.1%)                                  10 (29.4%)   2 (16.7%)   2 (25%)     0
  Tetracycline                    55 (94.8%)                                  31 (91.2%)   12 (100%)   8 (100%)    4 (100%)
  Cefoperazone                    17 (29.3%)                                  9 (26.5%)    4 (33.3%)   4 (50%)     0
  Cefazolin                       22 (37.9%)                                  14 (41.2%)   4 (33.3%)   4 (50%)     0
  Ticarcillin                     56 (96.6%)                                  33 (97.1%)   12 (100%)   7 (87.5%)   4 (100%)
  Ticarcillin/clavulanic acid     3 (5.2%)                                    2 (5.9%)     0           1 (3.6%)    0
  Aztreonam                       2 (3.4%)                                    0            1 (8.3%)    1 (3.6%)    0
  Ampicillin                      57 (98.3%)                                  33 (97.1%)   12 (100%)   8 (100%)    4 (100%)
  Chloramphenicol                 54 (93.1%)                                  31 (91.2%)   12 (100%)   7 (87.5%)   4 (100%)
  Trimethoprim/sulfamethoxazole   25 (43.1%)                                  16 (47.1%)   4 (33.3%)   3 (37.5%)   2 (50%)
  Levofloxacin                    1 (1.7%)                                    0            0           1 (12.5%)   0
  Cefepime                        0                                           0            0           0           0
  Imipenem                        0                                           0            0           0           0
  nitrofurantoin                  2 (3.4%)                                    2 (5.9%)     0           0           0
  Cefoxitin                       3 (5.2%)                                    3 (8.8%)     0           0           0
  Tobramycin                      7 (12.1%)                                   5 (14.7%)    2 (16.7%)   0           0
  Gentamicin                      5 (8.6%)                                    4 (11.2%)    1 (8.3%)    0           0
  Norfloxacin                     22 (37.9%)                                  16 (47.1%)   3 (25%)     3 (37.5%)   0
  Amikacin                        0                                           0            0           0           0

###### 

**Dominant antimicrobial resistance profiles of 58 *Shigella flexneri* serotype 2 variant isolates from different regions of China**.

  **Antimicrobial resistance profiles**         **Total No. (%) (*n* = 58)**   **Xinjiang No. (%) (*n* = 8)**   **Shanghai No. (%) (*n* = 34)**   **Henan No. (%) (*n* = 12)**   **Guangxi No. (%) (*n* = 4)**
  --------------------------------------------- ------------------------------ -------------------------------- --------------------------------- ------------------------------ -------------------------------
  TE/SXT                                        1 (1.7%)                       0                                1 (2.9%)                          0                              0
  TE/TIC/AMP/C                                  14 (24.1%)                     2 (25%)                          6 (17.6%)                         4 (33.3%)                      2 (50%)
  TIC/AMP/C/NOR                                 2 (3.4%)                       0                                2 (5.9%)                          0                              0
  TE/TIC/AMP/C/SXT                              8 (13.8%)                      1 (12.5%)                        2 (5.9%)                          3 (25%)                        2 (50%)
  TE/TIC/AMP/C/NOR                              3 (5.2%)                       1 (12.5%)                        2 (5.9%)                          0                              0
  TIC/AMP/C/SXT/NOR                             1 (1.7%)                       0                                1 (2.9%)                          0                              0
  TE/GEN/TIC/AMP/C/SXT                          1 (1.7%)                       0                                1 (2.9%)                          0                              0
  TE/TIC/AMP/C/SXT/NOR                          5 (8.6%)                       0                                5 (14.7%)                         0                              0
  CRO/TE/CFZ/TIC/AMP/C                          1 (1.7%)                       0                                1 (2.9%)                          0                              0
  CRO/TE/CFP/CFZ/AMP/SXT                        1 (1.7%)                       1 (12.5%)                        0                                 0                              0
  CRO/CFP/CFZ/TIC/TE/AMP/C                      2 (3.4%)                       0                                0                                 2 (16.7%)                      0
  CRO/TE/CFZ/TIC/AMP/C/SXT                      1 (1.7%)                       0                                1 (2.9%)                          0                              0
  TE/TIC/AMP/C/TO/GEN/SXT/NOR                   1 (1.7%)                       0                                0                                 1 (8.3%)                       0
  CRO/PIP/TE/CFP/CFZ/TIC/AMP/C                  1 (1.7%)                       0                                1 (2.9%)                          0                              0
  CRO/PIP/TE/CFP/CFZ/TIC/AMP/SXT                1 (1.7%)                       0                                1 (2.9%)                          0                              0
  CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR              1 (1.7%)                       0                                1 (2.9%)                          0                              0
  CRO/TE/CFP/CFZ/LEV/TIC/AMP/C/NOR              1 (1.7%)                       1 (12.5%)                        0                                 0                              0
  CRO/PIP/TE/CFP/CFZ//TOTIC/AMP/C/NOR           1 (1.7%)                       0                                0                                 1 (8.3%)                       0
  CRO/PIP/TE/CFZ/TO/TIC/TIM/AMP/C/NOR           1 (1.7%)                       0                                1 (2.9%)                          0                              0
  CRO/PIP/TE/CFP/CFZ/TIC/ATM/AMP/C/SXT          1 (1.7%)                       1 (12.5%)                        0                                 0                              0
  CRO/PIP/TE/CFP/CFZ/TIC/TIM/AMP/C/NOR          2 (3.4%)                       1 (12.5%)                        0                                 1 (8.3%)                       0
  CRO/TE/CFZ/FOX/TO/TIC/AMP/C/SXT/NOR           2 (3.4%)                       0                                2 (5.9%)                          0                              0
  CRO/PIP/TE/CFP/CFZ/FOX/TIC/AMP/C/NOR          1 (1.7%)                       0                                1 (2.9%)                          0                              0
  CRO/TE/CFZ/FOX/TO/GEN/TIC/AMP/C/SXT/NOR       2 (3.4%)                       0                                2 (5.9%)                          0                              0
  CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/TIM/AMP/C       1 (1.7%)                       0                                1 (2.9%)                          0                              0
  CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/TIM/AMP/C/NOR   1 (1.7%)                       0                                1 (2.9%)                          0                              0
  CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/AMP/C/SXT/NOR   1 (1.7%)                       0                                1 (2.9%)                          0                              0

Moreover, notable differences of antibiotic resistance profiles were also observed during the periods 2003--2008 and 2009--2013. Of the 58 serotype 2 variant strains, the resistance rate to cephalosporin and quinolones was 33.3% and 17.9% during 2003--2008, respectively, which increased to 47.4% and 78.9% during 2009--2013. The resistance rate to both cephalosporin and quinolones was 5.1% during 2003--2008, which increased to 42.1% during 2009--2013 (Table [4](#T4){ref-type="table"}).

###### 

**Resistance to quinolones or cephalosporin of 58 *S. flexneri* serotype 2 variant isolates from different regions of China during 2003--2008 and 2009--2013**.

  **Resistance to quinolones or cephalosporin**   **No. (%) isolates**   ***P*-value**                                                                                  
  ----------------------------------------------- ---------------------- --------------- ---------- ----------- ---------- ---------- --------- --- -------- ---------- -------
  Non                                             21 (53.8)              3 (15.8)        9 (42.9)   1 (7.7)     6 (66.7)   1 (33.3)   4 (100)   0   2 (40)   1 (33.3)   ≤0.01
  Cephalosporin                                   13 (33.3)              9 (47.4)        8 (38.1)   6 (46.2)    3 (33.3)   1 (33.3)   0         0   2 (40)   2 (66.7)   0.3
  Quinolones                                      7 (17.9)               15 (78.9)       4 (19)     12 (92.3)   3 (33.3)   2          0         0   2 (40)   1 (33.3)   ≤0.01
  Both                                            2 (5.1)                8 (42.1)        0          7 (53.8)    3 (33.3)   1 (33.3)   0         0   1 (20)   1 (33.3)   ≤0.01

MLST and PFGE analysis
----------------------

To determine the phylogenetic relationship of these serotype 2 variant strains, an extended MLST scheme of 15 genes was performed. We found that all the isolates in this study belonged to the same sequence type, which was designated ST100. ST100 also contained multiple other serotypes such as 1a, 1c, 2a, 2b, and Y, suggesting that ST100 has been circulating among different *S. flexneri* serotypes for a long time in China. PFGE was further performed to determine genetic relatedness among the isolates of serotype 2 variant and other serotypes. With a similarity of 80%, all the serotype 2 variant strains except two isolates (SH05Sh584 and SH12Sh282) formed a single cluster (containing 2a and 2b isolates). This result suggested that the serotype 2 variant strains were closely related to serotype 2a and 2b. Besides, the 58 *S. flexneri* serotype 2 variant isolates generated 45 PFGE patterns (Figure [3](#F3){ref-type="fig"}), suggesting a high genetic diversity among the serotype 2 variant strains.

![**Pulsed-field gel electrophoresis dendrogram and the antibiotic resistance profile of *S. flexneri* serotype 2 variant, 2a, and 2b isolates**. The original number, origin, serotype, and isolation year are indicated for each strain.](fmicb-06-00435-g0003){#F3}

Molecular analysis of antibiotic-resistance determinants and integrons
----------------------------------------------------------------------

Twenty-two of 58 isolates showing resistance to cephalosporin were selected to test for antibiotic-resistance determinants and integrons, including the *bla*~VIM~, *bla*~NDM~, *bla*~SHV~, *bla*~TEM~, *bla*~OXA~, *bla*~CTX−M~, *intI1*, and *intI2* gene regions (Table [5](#T5){ref-type="table"}). PCR screenings showed that all strains were negative for *bla*~SHV~, *bla*~VIM~, and *bla*~NDM~, but positive for *bla*~TEM~, *bla*~OXA~, and *bla*~CTX−M~. Sequencing results using primers amplifying the whole *bla*~TEM~ gene showed 100% identity with the *bla*~TEM−1~ gene. All except two isolates from Shanghai and one isolate from Xinjiang harbored *bla*~OXA−1~. Besides, 18 isolates contained the *bla*~CTX−M~ gene; nine isolates from Shanghai, two from Xinjiang, and one from Henan harbored *bla*~CTX−M−14~; three isolates from Shanghai and one isolate from Henan harbored *bla*~CTX−M−3~; and one isolate from Xinjiang and one isolate from Henan harbored *bla*~CTX−M−79~. All isolates harbored class 1 integrons with *bla*~OXA−30~ and *aadA1* gene cassettes, and one isolate from Shanghai harbored *aacA4* and *cmlA1* gene cassettes. All of the isolates harbored class 2 integrons following *dfrA1*, *sat1*, and *aadA1* gene cassettes. In 22 quinolone-resistant isolates, no point mutations in QRDRs of *gyrB* and *parE* were found, but point mutations in QRDRs of *gyrA* and *parC* were identified in each resistant isolate. All of the norfloxacin-resistant isolates had the gyrA mutation of Ser83Leu and the parC mutations of Ser80Ile and His211Tyr in our study. Interestingly, the strain 2006040 (the only isolate resistant to levofloxacin) from Xinjiang and strain HN08096 from Henan had the gyrA mutation of Asp87Asn, while the rest of the strains except strain HN09103 had the gyrA mutation of Asp87Gly. Only two species of PMQR determinants \[*qnrS* and *aac(6′)-Ib-cr*\] were identified. All of the isolates harbored the *aac(6′)-Ib-cr* gene, and only two isolates from Shanghai harbored *qnrS*. Sequencing analysis determined that the two *qnrS* genes were *qnrS1* (Table [6](#T6){ref-type="table"}).

###### 

**Antibiogram and molecular analysis of the antibiotic-resistance determinants and integrons of *S. flexneri* serotype 2 variant isolates with resistance to cephalosporin**.

  **Strain No**.                           **Antibiogram**                               **Antibiotic-resistant determinants and integrons present**
  ---------------------------------------- --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  **STRAINS RESISTANT TO CEPHALOSPORIN**                                                 
  2004607                                  CRO/TE/CFP/CFZ/AMP/SXT                        *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~TEM1~
  SH05Sh584                                CRO/TE/CFZ/TIC/AMP/C/SXT                      *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~
  HN08166                                  CRO/TE/CFP/CFZ/TIC/AMP/C                      *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~
  HN08175                                  CRO/TE/CFP/CFZ/TIC/AMP/C                      *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~
  SH05Sh582                                CRO/PIP/TE/CFP/CFZ/TIC/AMP/C                  *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-3~
  SH05Sh10                                 CRO/PIP/TE/CFP/CFZ/TIC/AMP/C                  *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~
  SH05Sh9                                  CRO/PIP/TE/CFP/CFZ/TIC/AMP/SXT                *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~TEM1~, *bla*~CTX-M-14~
  SH05sh375                                CRO/PIP/TE/CFP/CFZ/TIC/AMP/SXT                *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~TEM1~, *bla*~CTX-M-14~
  SH05Sh39                                 CRO/PIP/TE/CFP/CFZ/TIC/AMP/SXT                *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~
  SH09sh2-2                                CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR              *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~
  SH12Sh104                                CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR              *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~
  2006040                                  CRO/TE/CFP/CFZ/LEV/TIC/AMP/C/NOR              *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~
  SH05sh48                                 CRO/PIP/TE/CFZ/TO/TIC/TIM/AMP/C               *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-3~
  2012262                                  CRO/PIP/TE/CFP/CFZ/TIC/TIM/AMP/C/NOR          *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~
  HN08096                                  CRO/PIP/TE/CFP/CFZ/TO/TIC/AMP/C/NOR           *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-3~
  SH13Sh70                                 CRO/TE/CFZ/FOX/TO/TIC/AMP/C/SXT/NOR           *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~
  SH12Sh111                                CRO/PIP/TE/CFP/CFZ/FOX/TIC/AMP/C/NOR          *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~
  2011154                                  CRO/PIP/TE/CFP/CFZ/TIC/ATM/AMP/C/SXT          *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-79~
  HN12152                                  CRO/PIP/TE/CFP/CFZ/TIC/ATM/AMP/C/NOR          *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-79~
  SH05sh394                                CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/TIM/AMP/C       *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-3~
  SH13Sh32                                 NIT/TE/CFZ/FOX/TO/GEN/TIC/AMP/C/SXT/NOR       *IntI1* (*bla*~OXA-30~+*aadA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~
  SH12Sh160                                CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/AMP/C/SXT/NOR   *IntI1* (*bla*~OXA-30~+*aadA1*; *aacA4+cmlA1*)*, IntI2* (*dfrA1+sat1+aadA1*), *bla*~OXA1~, *bla*~TEM1~, *bla*~CTX-M-14~

###### 

**Antibiogram and molecular analysis of the antibiotic-resistance determinants and integrons of *S. flexneri* serotype 2 variant isolates with resistance to fluoroquinolone**.

  **Strain No**.                             **Antibiogram**                               **PMQR determinant**   **Amino acid in QRDR**                     
  ------------------------------------------ --------------------------------------------- ---------------------- ------------------------ ----- ----- ----- -----
  **STRAINS RESISTANT TO FLUOROQUINOLONE**                                                                                                                   
  SH07Sh007                                  TIC/AMP/C/NOR                                 \+                     --                       Ile   Leu   Gly   Tyr
  SH08Sh265                                  TIC/AMP/C/NOR                                 \+                     --                       Ile   Leu   Gly   Tyr
  2006095                                    TE/TIC/AMP/C/NOR                              \+                     --                       Ile   Leu   Gly   Tyr
  SH12Sh282                                  TE/TIC/AMP/C/NOR                              \+                     --                       Ile   Leu   Gly   Tyr
  SH09sh188-2                                TE/TIC/AMP/C/NOR                              \+                     --                       Ile   Leu   Gly   Tyr
  SH12Sh219                                  TIC/AMP/C/SXT/NOR                             \+                     --                       Ile   Leu   Gly   Tyr
  SH05sh577                                  TE/TIC/AMP/C/SXT/NOR                          \+                     \+                       Ile   Leu   Gly   Tyr
  SH11sh473                                  TE/TIC/AMP/C/SXT/NOR                          \+                     --                       Ile   Leu   Gly   Tyr
  SH12Sh119                                  TE/TIC/AMP/C/SXT/NOR                          \+                     --                       Ile   Leu   Gly   Tyr
  SH13Sh40                                   TE/TIC/AMP/C/SXT/NOR                          \+                     --                       Ile   Leu   Gly   Tyr
  SH05sh585                                  TE/TIC/AMP/C/SXT/NOR                          \+                     --                       Ile   Leu   Gly   Tyr
  HN09103                                    TE/TO/GEN/TIC/AMP/C/SXT/NOR                   \+                     --                       Ile   Leu   Asp   Tyr
  SH09sh2-2                                  CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR              \+                     --                       Ile   Leu   Gly   Tyr
  SH12Sh104                                  CRO/PIP/TE/CFP/CFZ/TIC/AMP/C/NOR              \+                     --                       Ile   Leu   Gly   Tyr
  2006040                                    CRO/TE/CFP/CFZ/LEV/TIC/AMP/C/NOR              \+                     --                       Ile   Leu   Asn   Tyr
  SH13Sh70                                   CRO/TE/CFZ/FOX/TO/TIC/AMP/C/SXT/NOR           \+                     --                       Ile   Leu   Gly   Tyr
  HN08096                                    CRO/PIP/TE/CFP/CFZ/TO/TIC/AMP/C/NOR           \+                     --                       Ile   Leu   Asn   Tyr
  HN12152                                    CRO/PIP/TE/CFP/CFZ/TIC/ATM/AMP/C/NOR          \+                     --                       Ile   Leu   Gly   Tyr
  2012262                                    CRO/PIP/TE/CFP/CFZ/TIC/TIM/AMP/C/NOR          \+                     --                       Ile   Leu   Gly   Tyr
  SH12Sh111                                  CRO/PIP/TE/CFP/CFZ/FOX/TIC/AMP/C/NOR          \+                     \+                       Ile   Leu   Gly   Tyr
  SH13Sh32                                   NIT/TE/CFZ/FOX/TO/GEN/TIC/AMP/C/SXT/NOR       \+                     --                       Ile   Leu   Gly   Tyr
  SH12Sh160                                  CRO/PIP/TE/CFP/CFZ/TO/GEN/TIC/AMP/C/SXT/NOR   \+                     --                       Ile   Leu   Gly   Tyr

Discussion {#s4}
==========

The emergence of MDR strains has become a serious problem and has complicated the selection of empirical treatment for shigellosis. In the present study, the serotype 2 variant isolates were highly resistant to ampicillin, chloramphenicol, tetracycline, and ticarcillin, and 98.3% of these isolates showed MDR profiles. One of the reasons for the rapid accumulation of resistance is excessive or inappropriate use of antibiotics in outpatients in China (Pickering, [@B24]; Zhang et al., [@B38]).

Our study further indicates that current resistance patterns have changed and that empirical therapy should keep pace with these changes. According to previous results, fluoroquinolones and third-generation cephalosporins are probably the best choice for empiric treatment of severe gastrointestinal infections caused by pathogenic bacteria (Gendrel et al., [@B12]). However, the resistance rates of these isolates to fluoroquinolones and third-generation cephalosporins in the serotype 2 variant strains have increased at an alarming rate, and continuous surveillance of the resistance pattern will be essential to choose the appropriate antimicrobial therapy.

The increasing antibiotic resistance rate led us to study the genetics and mechanisms of antibiotic resistance. The horizontal transfer of integrons may account for the dissemination of resistance genes, and resistance to some antibiotics is associated with the presence of class 1 and class 2 integrons containing resistance gene cassettes (Ke et al., [@B17]). In the current study, *bla*~OXA−30~ and *aadA1* were detected in the gene cassettes of class 1 integrons, and *dfrA1+sat1+aadA1* was detected in the gene cassettes of class 2 integrons. In addition, of the 22 cephalosporin-resistant isolates, 100% harbored the *bla*~TEM−1~ resistance gene, 81.8% harbored the *bla*~CTX~ resistance gene, and 90.9% harbored the *bla*~OXA~ resistance gene. Additionally, the strong ability to acquire resistance genes facilitated the survival of bacteria under the pressure of various antibiotics. The *bla*~TEM−1~ gene was detected in all of the ESBL-producing isolates; this gene exists at high frequencies in antibiotic-resistant bacteria across the globe and confers resistance to penicillin and other β-lactamase antibiotics (Barlow and Hall, [@B4]). OXA-type β-lactamases confer resistance to ampicillin and cephalothin, and they are characterized by high hydrolytic activity against oxacillin and cloxacillin (Bradford, [@B5]). Sequencing analysis showed that all of the *bla*~OXA~ genes were *bla*~OXA−1~, indicating the host specificity for this subtype in *S. flexneri*, which is consistent with the result of a previous study (Siu et al., [@B31]).

Fluoroquinolone resistance in *Enterobacteriaceae* has been mostly attributed to modifications in the QRDRs of the *gyr*A and *par*C genes and/or PMQR determinants such as *qnr* and \[*aac(6′)-Ib-cr*\] (Folster et al., [@B8]). In the current study, 95% of the quinolone-resistant *Shigella* isolates had at least three point mutations in *gyr*A (Ser83Leu, Asp87Gly/Asn, and His211Tyr) and *par*C (Ser80Ile). Furthermore, different amino acid substitutions at the same position may result in different quinolone susceptibility levels (Ruiz, [@B30]). The His211Tyr mutation in gyrA was detected in resistant *S. flexneri* serotype 2a strains from Bangladesh (Azmi et al., [@B3]). Notably, all of the quinolone-resistant isolates in our study had the gyrA mutation of His211Tyr. PMQR determinants are located on mobile genetic elements (i.e., plasmids), which may allow for dissemination among *Shigella* (Folster et al., [@B8]). The presence of the *qnr* gene can facilitate the selection of chromosomal mutations that cause quinolone resistance (Jacoby et al., [@B16]; Martinez-Martinez et al., [@B20]). Worldwide, *S. flexneri* serotypes 1a, 2a, 2b, and 4c carrying the *qnrS* gene were reported with low incidence (Hata et al., [@B13]; Pu et al., [@B25]). In our study, only two strains from Shanghai carried the *qnrS1* gene with a percentage of 3.4%, and one of the *qnrS*-positive strains was the only isolate that was resistant to levofloxacin. The *aac(6′)-Ib-cr* gene is identified in many Enterobacteriaceae and is responsible for low-level resistance to fluoroquinolones (Frasson et al., [@B9]). The *aac(6′)-Ib-cr*--positive *S. flexneri* 2a strain was first isolated in 1998 (Pu et al., [@B25]), and all of the 17 quinolone-resistant isolates were *aac(6′)-Ib-cr*--positive, suggesting that the *aac(6′)-Ib-cr* gene had been present in China for many years.

Serotype conversion is a major mechanism for *S. flexneri* to escape protective host immune responses, which may drive the emergence of novel and atypical serotypes under pressure (Allison and Verma, [@B2]). Based on phenotypic and genotypic analysis, the serotype 2 variant is likely to originate from serotypes 2a and 2b, which have experienced changes in their genome to adapt to altered environmental conditions. The serotype 2 variant was circulated as a major serotype during our 11-year study period, and the widespread dissemination of this serotype poses a serious threat to public health not only in China but also in the world.

In summary, studies on the serotype 2 variant have become very important owing to the increased epidemic frequency and the prevalence of MDR strains. In view of the fact that this serotype was prevalent in several provinces in China, it is likely to provoke a major crisis because MDR clones can and may have already spread to other countries. Therefore, continuous surveillance will be needed to determine the distribution and resistance development of this serotype so as to understand the actual disease burden and provide guidance for the clinical treatment of shigellosis.
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